Search

Displaying results 1371 - 1380 of 1613 in total
  1. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

  2. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    [L46048,L46058] In December 2025, the indication was expanded to include adults and pediatric patients six years and older with severe aplastic anemia (SAA). [L46048,L54688]

  3. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of th...

  4. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix, Inc.

  5. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  6. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administer...

  7. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and a...

  8. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S....

  9. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met).

  10. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64117,L64107,L64116] It is the first next-generation oral SERD and complete ER antagonist approved in the first-line setting, and the only one approved for use with all three widely approved CDK4/6 inhibitors